摘要
卡他莫拉菌(MC)已被证实为呼吸道感染的致病菌之一,且与中耳炎、呼吸道感染、感染性心内膜炎等严重感染性疾病有关,该菌不但可导致医院感染,而且可引起暴发流行。MC致病机制主要与外膜、黏蛋白、受体蛋白、补体耐受、生物膜等有关。目前,在广谱抗菌药物和免疫抑制剂普遍应用的环境下,该菌耐药性状况日益严重,给临床诊断治疗造成了较大阻碍,产β-内酰胺酶是MC耐药的主要原因之一。在MC感染者的抗菌药物治疗中,建议首选氨基糖苷类抗菌药物或第3代头孢类抗菌药物,同时应根据患者病情及药敏试验结果合理选用抗菌药物。
Moraxella catarrhalis(MC)has been confirmed to be one of the pathogenic bacteria of respiratory tract infection,and relates to serious infectious diseases such as otitis media,respiratory tract infection,infective endocarditis.MC can not only cause nosocomial infection,but also cause outbreaks.Its pathogenic mechanism mainly relates to outer membrane,mucin,receptor protein,complement tolerance,biological film and so on.At present,in the environment of widespread use of broad-spectrum antibiotic and immunosuppressant,the drug resistance of MC has become increasingly serious,which has caused great obstacles to clinical diagnosis and treatment.β-lactamase production is one of the main reasons for drug resistance of MC.In the treatment of MC infection,aminoglycoside antibiotics or the third generation cephalosporin antibiotics are recommended as the first choice.At the same time,antibiotics should be selected reasonably according to the patient's condition and drug sensitivity test.
作者
史简
项玉涵
王丽丽
杨霞霞
李雪
李文静(综述)
陆书华(审校)
SHI Jian;XIANG Yuhan;WANG Lili;YANG Xiaxia;LI Xue;LI Wenjing;LU Shuhua(School of Clinical Medicine,Jining Medical University,Jining,Shandong 272013,China;Department of Clinical Laboratory,Affiliated Hospital of Jining Medical University,Jining,Shandong 272000,China;Qixia Center for Disease Control and Prevention,Yantai,Shandong 265300,China)
出处
《检验医学与临床》
CAS
2023年第22期3386-3389,共4页
Laboratory Medicine and Clinic
基金
山东省济宁市重点研发计划项目(2021YXNS027,2022YXNS023)
山东省济宁医学院附属医院苗圃科研计划项目(MP-MS-2022-020)。
关键词
卡他莫拉菌
中耳炎
慢性阻塞性肺疾病
致病机制
耐药性
Moraxella catarrhalis
otitis media
chronic obstructive pulmonary disease
pathogenic mechanism
drug resistance
